In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Here to help break down this new painkiller is Dr. Sean Mackey. He’s a Professor of Anesthesiology and Medicine at Stanford ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...

The approval was announced in an FDA press release, and it will be sold under the brand name Journavx by Vertex Pharmaceuticals. This painkiller's approval reflects the FDA’s commitment to ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in more than 20 years. “Today’s approval is an important public health ...

Credit: Vertex The active ingredient in Journavx is suzetrigine, a sodium channel blocker. The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug ...

JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years -- -- JOURNAVX is an effective and well ...